ABC | Volume 114, Nº2, February 2020

Review Article Romano et al. Myocardial alterations in familial lipodystrophy Arq Bras Cardiol. 2020; 114(2):305-312 1. Lupsa BC, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in congenital and acquired generalized lipodystrophy: A clinical assessment. Medicine (Baltimore) . 2010;89(4):245-50. 2. Nelson MD, Victor RG, Szczepaniak EW, Simha V, Garg A, Szczepaniak LS. Cardiacsteatosisand leftventricularhypertrophy inpatientswithgeneralized lipodystrophy as determined by magnetic resonance spectroscopy and imaging. Am. J. Cardiol. 2013;112(7):1019-24. 3. Garg A. Clinical review#: Lipodystrophies: Genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313-25. 4. Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: Pathophysiology and advances in treatment. Nat Rev Endocrinol. 2011;7(3):137-50 5. Garg A, Peshock RM, Fleckenstein JL. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (dunnigan variety). J. Clin. Endocrinol. Metab. 1999;84(1):170-4. 6. Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet. 2014;59((1):16-23. 7. Leão LMC, Alencar RC, Rodrigues GdC, Bouzas I, Gallo P, Rossini A. Lipodistrofia parcial familiar do tipo dunnigan: Atenção ao diagnóstico precoce. Rev Bras Ginecol e Obstet . 2011;33((2):99-103. 8. VantyghemMC, Pigny P, Maurage CA, Rouaix-Emery N, Stojkovic T, Cuisset JM, et al. Patients with familial partial lipodystrophy of the dunnigan type due to a lmna r482w mutation show muscular and cardiac abnormalities. . Clin Endocrinol Metab. 2004;89((11):5337-46. 9. Vadrot N, Duband-Goulet I, Cabet E, Attanda W, Barateau A, Vicart P, et al. The p.R482w substitution in a-type lamins deregulates srebp1 activity in dunnigan-type familial partial lipodystrophy. Hum Mo Genet. 2015;24:(7)2096-109. 10. PonteC.Neuropatiaautonômicacardiovascularprecoceem indivíduoscom lipodistrofia generalizada congênita. Tese. Fortaleza:Universidade Federal do Ceará; 2016. 11. Sisakian H. Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies. World J Cardiol. 2014;6(6):478-94. 12. NishidaK,OtsuK. Inflammationandmetaboliccardiomyopathy. Cardiovasc. Res. 2017;113(4):389-98. 13. Trachanas K, Sideris S, Aggeli C, Poulidakis E, Gatzoulis K, Tousoulis D, et al. Diabetic cardiomyopathy: From pathophysiology to treatment. Hellenic J Cardiol. 2014;55(5):411-21. 14. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta . 2010;1801(3):311-9. 15. Bidault G, Garcia M, Vantyghem MC, Ducluzeau PH, Morichon R, Thiyagarajah K, et al. Lipodystrophy-linked lmna p.R482wmutation induces clinicalearlyatherosclerosisand invitroendothelialdysfunction. Arterioscler. Thromb Vasc Biol. 2013;33(9):2162-71. 16. Rego AR, Rego MAC, Faria CA; Baracho MFP; Egito EST; Mesquita ET, et al. Alterações cardiovasculares e metabólicas da lipodistrofia generalizada congênita (síndrome de seip-berardinelli). Rev SOCERJ . 2007;20(2):1-6. 17. Viegas RF, Diniz RV, Viegas TM, Lira EB, Almeida DR. Cardiac involvement in total generalized lipodystrophy (berardinelli- seip syndrome). Arq Bras Cardiol. 2000;75(3):243-8. 18. FrigulsB,CoroleuW,delAlcazarR,HilbertP,VanMaldergemL,Pintos-MorellG. Severecardiacphenotypeofberardinelli-seipcongenitallipodystrophyinaninfant withhomozygouse189xbscl2mutation. EurJMedGenet. 2009;52(1):14-6. 19. KhalifeWI, MourtadaMC, Khalil J. Dilated cardiomyopathy andmyocardial infarction secondary to congenital generalized lipodystrophy. Tex Heart Inst J. 2008;35(2):196-9. 20. Debray FG, Baguette C, Colinet S, VanMaldergemL, Verellen-Dumouin C. Early infantile cardiomyopathy and liver disease: A multisystemic disorder caused by congenital lipodystrophy. Mol. Genet Metab. 2013;109(2):227-9. 21. BhayanaS,SiuVM,JoubertGI,ClarsonCL,CaoH,HegeleRA.Cardiomyopathy in congenital complete lipodystrophy. Clin Genet. 2002;61(4):283-7. 22. Madej-Pilarczyk A, Niezgoda A, Janus M,Wojnicz R, Marchel M, Fidzianska A,etal.Limb-girdlemuscular dystrophywithsevereheart failureoverlapping with lipodystrophy in a patient with lmna mutation p.Ser334del. J Apll Genetics. . 2017;58(1)87-91. 23. Pan H, Richards AA, Zhu X, Joglar JA, Yin HL, Garg V. A novel mutation in lamin a/c is associated with isolated early-onset atrial fibrillation and progressive atrioventricular block followed by cardiomyopathy and sudden cardiac death. Heart Rhythm . 2009;6(5):707-10. 24. Rego AG, Mesquita ET, Faria CA, RegoMA, BarachoMde F, Santos MG,et al. Cardiometabolic abnormalities in patients with berardinelli-seip syndrome]. Arq Bras Cardiol. 2010;94(1):109-18. 25. Sims-Williams HP, NyeHJ, Walker PR. Dilated cardiomyopathy and skeletal myopathy: Presenting features of a laminopathy. BMJ Case Rep. 2013;jan 17;:pii bcr 2012007574. 26. Scatteia A, Pagano C, Pascale C, Guarini P, Marotta G, Perrone-Filardi P, et al. Asymmetric hypertrophic cardiomyopathy in generalized lipodystrophy. Int J Cardiol. 2016 Jan 1;202:724-5. 27. JoubertM,JaguB,MontaigneD,MarechalX,TesseA,AyerA,etal.Thesodium- glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophicmousemodel. Diabetes . 2017;66(4):1030-40. References Study Association This article is part of a scientific initiation thesis submitted by Paula Ananda Inês Chacon, from FMRP-USP. Ethics approval and consent to participate This article does not contain any studies with human participants or animals performed by any of the authors. 311